Timeline
Solvonis Therapeutics
Solvonis Therapeutics' stimulant use disorder candidate outperforms in early results
Solvonis Therapeutics hits key PK milestone for esketamine AUD programme
Solvonis to prioritise Phase 3 for lead asset
Solvonis Therapeutics welcomes US executive order
Solvonis secures another US patent for PTSD programme
More in Pharma
Shield Therapeutics takes full US control of ACCRUFeR
The iron deficiency specialist will absorb its co-commercialisation partner's sales force and retain all US gross profit from ACCRUFeR, paying Viatris a royalty instead of a profit share.